Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 di ... Read more

Novo Nordisk A/S: Saxenda® demonstrated improvements in BMI and body weight in a ... Read more

Resolutions from the Annual General Meeting of Novo Nordisk A/S ... Read more

Novo Nordisk pauses the clinical trials investigating concizumab (anti-TFPI mAB) ... Read more

Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 di ... Read more

Novo Nordisk A/S - Share repurchase programme ... Read more

Resolutions from the Annual General Meeting of Novo Nordisk A/S ... Read more

Novo Nordisk A/S – Share repurchase programme ... Read more

Financial statements for the first three months of 2020,

Silent period,

Financial statement for the first six months of 2020,

Silent period,